Background: The aim of this study is to determine feasibility and efficacy of the combination regimen gemcitabine, oxaliplatin, and paclitaxel (GOP) in patients with cisplatin-refractory or multiply relapsed germ-cell tumors. Patients were pretreated with a median of two lines of platin-based chemotherapy (range, 1-3), and 78% had relapsed after HDCT/PBSCT.
introduction Today, 70%-80% of patients with metastatic germ-cell tumors achieve long-term survival with cisplatin-based chemotherapy [1, 2] . Patients suffering from relapse after first-line cisplatin-based chemotherapy may still be cured in 10%-50% of cases with salvage chemotherapy. Patients progressing during or relapsing after salvage chemotherapy, however, exhibit a very poor prognosis, and long-term survival is rare [3] . Therefore, the evaluation of new active drugs and treatment combinations remains a priority for these patients. Various chemotherapeutic agents have been evaluated in intensely pretreated or cisplatin-refractory patients. As single agents, only orally administered etoposide or i.v. paclitaxel, gemcitabine, and, most recently, oxaliplatin have been shown to be active with selected patients achieving prolonged survival [4] [5] [6] [7] [8] [9] .
The German Testicular Cancer Study Group (GTCSG) systematically conducted a series of consecutive phase II trials in heavily pretreated germ-cell tumor patients which tested a number of agents and combinations each on the basis of a preclinical rationale. Gemcitabine, oxaliplatin, and paclitaxel (GOP) were developed as single agents in consecutive phase II trials [6, 7, 9] . Paclitaxel has demonstrated its activity in refractory or relapsed germ-cell tumor patients in several clinical trials and has become part of different salvage combination chemotherapy regimen, e.g. in combination with platinum and ifosfamide [10, 11] . For single-agent gemcitabine, two phase II studies from Germany and the United States have shown response rates of 15%-20% in refractory patients [7, 8] . On the basis of preclinical investigations indicating an incomplete cross-resistance between oxaliplatin and cisplatin [12] , a GTCSG phase II trial evaluated oxaliplatin given at a dose of 130 mg/m 2 every 2 weeks in cisplatin-refractory or relapsed patients, yielding a response rate of 19% [9] . With single-agent activity for both gemcitabine and oxaliplatin and in vitro analyses demonstrating supraadditive synergistic effects of oxaliplatin in combination with gemcitabine, both agents were combined within a subsequent GTCSG phase II trial [13, 14] . These two drug regimens were proven to be feasible with acceptable toxicity in this heavily pretreated patient group and a high response rate of 46% was observed including several long-term survivors [14] .
These results formed the rationale for the present trial which evaluated the combination of all three active agents, GOP, in patients with relapsed or refractory germ-cell tumors.
patients and methods
Eligibility criteria for this open-label, multicenter phase II trial included histologically confirmed seminomatous or nonseminomatous germ-cell tumor, relapse within 3 months after cisplatin-based chemotherapy, tumor progression during or relapse after salvage high-dose chemotherapy (HDCT), tumor progression during salvage cisplatin-based chemotherapy, or ineligibility for cisplatin-based or HDCT due to severe comorbidities. Patients had to have measurable disease and documented tumor progression on X-ray, ultrasound, computed tomography, or magnetic resonance imaging. An elevation of alpha-fetoprotein (AFP) or beta-human chorionic gonadotropin (b-HCG) was accepted as measurable disease if an increase of at least 25% within 3 weeks before study inclusion had been observed. Further inclusion criteria were a Karnofsky performance status of at least 60%, a life expectancy of >3 months, and age between 18 and 70 years. An adequate bone marrow function (leukocytes > 2500/ll, thrombocytes > 100 000/ll), liver function (bilirubin level < 1.5-fold the upper normal limit), and renal function (serum creatinine clearance < 1.5-fold the upper normal limit) were mandatory. All patients gave written informed consent. The study was approved by the ethics committees of the Universities of Tuebingen and Hamburg-Eppendorf, Germany, as well as by the local ethics committees of the participating centers.
Gemcitabine was given at a dose of 800 mg/m 2 as a 30-min infusion and paclitaxel at a dosage of 80 mg/m 2 as a 1-h infusion, both on days 1 and 8 of a 3-week cycle. Oxaliplatin was administered only on day 1 with 130 mg/m 2 i.v. >2 h. Antiemetic prophylaxis was left to the decision of the treating physician, but a combination of a 5-HT 3 antagonist and dexamethasone was proposed. Prophylaxis for paclitaxel included anaphylaxis with 20 mg dexamethasone i.v. for 30 min and 50 mg diphenhydramine plus 300 mg cimetidine i.v. for 20 min before the infusion of paclitaxel was mandatory. Patients responding to study treatment were planned to receive two cycles beyond the best response up to a maximum of eight cycles. GOP chemotherapy was administered at full dose on days 1 and 8 if leukocytes were >3000/ll and thrombocytes >100 000/ll. If thrombocytes were 50 000-100 000/ll or leukocytes 1500-3000/ll on day 8 of the chemotherapy cycle, the doses of gemcitabine and paclitaxel were reduced to 75%. In case of thrombocytes <50 000/ll or leukocytes <1500/ll on day 8, study treatment was hold until complete regeneration and a prophylaxis with hematopoetic growth factors [granulocyte colonystimulating factor (G-CSF)] was given in subsequent cycles. If the nadir of granulocytes during any cycle of study treatment was <500/ll, G-CSF was strongly recommended and if the nadir of thrombocytes was <50.000/ll, oxaliplatin and gemcitabine had to be reduced by 25% in all further cycles. Scheduling and duration of G-CSF therapy were left to the treating physician. Patients were taken off study if no hematopoetic regeneration occurred within 2 weeks after the end of the previous cycle.
Both oxaliplatin and paclitaxel were reduced to 75% dose if peripheral neuropathy Common Toxicity Criteria (CTC) grade II occurred. Both drugs were stopped in case of neuropathy grade III or IV. Gemcitabine was continued regardless of any grade of peripheral neuropathy, but had to be stopped if serum creatinine increased 1.5-fold above the upper normal limit. In all other cases of nonhematologic toxic grade II-IV, apart from alopecia and nausea, study treatment had to be held until recovery of symptoms to CTC grade 0 or I and all three drugs were reduced by 25% in the subsequent cycles.
Pretreatment evaluation consisted of medical history, assessment of the Karnofsky performance status and preexisting toxic effects, physical examination and electrocardiogram, and routine laboratory including blood cell counts, liver function tests, creatinine clearance, electrolytes, and tumor markers (AFP and b-HCG).
definitions Disease was considered cisplatin refractory when at least tumor stabilization or a remission had been achieved, but tumor progression occurred again within 4 weeks of the last cisplatin-based chemotherapy. Disease was considered absolutely cisplatin refractory when tumor progression had occurred while patients were receiving cisplatin-based therapy [15, 16] .
response assessment
Response assessment was carried out following every other cycle. Toxicity was assessed after each cycle. Response and toxicity were graded according to World Health Organization and National Cancer Institute-CTC (version 2.0) criteria, respectively. In addition, patients with reduction of the size of a tumor lesion and normalization of previously elevated tumor markers were considered partial remission (PR) with tumor marker normalization (PR negative). A reduction ‡50% in the sum of the perpendicular diameters of measurable disease plus a tumor marker decrease for at least 1 month, but without complete normalization, was considered as a marker-positive PR (PR positive). If elevated markers were the only evidence of progressive disease, a decrease of at least 90% was required for a PR. Levels of serum tumor markers were measured every 3 weeks. All responses as well as the diagnosis of stable disease had to be confirmed after a 4-week interval. All patients were scheduled to receive at least two cycles of treatment. If the clinical situation after one cycle indicated tumor progression and if in these cases a significant marker (50%) and/or radiological progression (25%), however, had occurred already after one cycle, the treatment was stopped and the patient was classified as having progressive disease.
statistical considerations
The primary end point of this study was response rate. Tolerability, progression free, and overall survival time represented secondary end points. An optimal Simon two-stage design was used to determine the number of patients required [17] . Assuming a response rate of clinical interest of ‡40%, a minimal response rate of 20%, a probability of 5% for rejecting an active drug combination (type II error), and a probability of 20% to further evaluate an ineffective drug combination (type I error), 18 patients had to be enrolled into the first cohort. If <4 responses to study therapy were observed among the first 18 patients, the study was to be terminated. If an objective remission occurred in at least Table 1 . All patients had previously received a median number of two (range, 1-3) platinum-based regimens. Seventy-eight percent of patients had relapsed after HDCT with peripheral blood stemcell transplantation either within the primary treatment (39%) or as salvage regimen (39%). Five patients (12%) had progressed during cisplatin-based chemotherapy (absolute cisplatin refractory) and nine (23%) had progressed within 4 weeks after completion of cisplatin-based chemotherapy (cisplatin refractory). Another 38% of patients had tumor progression between 5 and 12 weeks after cisplatin-based chemotherapy. At the time of study inclusion, 10% of patients each had bone and central nervous system metastases.
A total of 150 cycles of GOP were applied with a median number of four cycles per patient (range, 1-7). Study treatment was stopped due to tumor progression in 54% and for withdrawal of consent or unacceptable toxicity in 5% of the patients. A complete remission (CR) was observed in 5% of the patients, 34% achieved a marker-negative, and 12% a tumor marker-positive PR as best response, resulting in an overall response rate of 51% (95% confidence interval 35% to 67%). The first of the two CR patients had initially presented with a stage IIC nonseminoma and had received three cycles of cisplatin/etoposide/bleomycin (PEB). He attained a markernegative remission and underwent residual tumor resection showing necrosis only. He relapsed 6 months later and while receiving salvage etoposide/ifosfamide/cisplatin (VIP) chemotherapy, the patient progressed further. Classified as absolutely cisplatin-refractory disease, he was started on GOP and achieved a continuous CR. The second patient initially presented with good prognosis metastatic disease. He progressed shortly after three cycles of PEB and went on to salvage HDCT. He relapsed a second time 7 months after HDCT and subsequently achieved a continuous CR to GOP. In five other responding patients, a complete tumor resection was feasible after completion of treatment, resulting in an overall rate of complete responses of 17%. Another three responding patients had an incomplete resection of their residual lesions. They completed treatment and are alive with disease but progression free at the time of last follow-up. Table 2 summarizes the characteristics of all six long-term responding patients.
After a median follow-up of 5 months (range, 0-20), 17% of the patients are still disease free with a median response duration of 8 months (range, 3 to 17+), 24% are alive with disease, 57% have died due to disease, and one patient (2%) committed suicide. Median progression-free survival time was 3 months (range, 1 to 17+) and the median overall survival was 6 months (range, 1 to 19+).
Combination chemotherapy with GOP was given in 51% of cycles without dose reduction and in 79% without treatment 
discussion
Despite the overall success of cisplatin-based chemotherapy in patients with metastatic germ-cell cancer, the prognosis for cisplatin-refractory patients remains poor. Currently, no standard salvage chemotherapy exists for these patients and treatment options are very limited [3, 18] . Various doublet combinations of the active agents GOP have been tested in clinical trials in recent years [14, [19] [20] [21] [22] [23] [24] . The present study is the first successfully completed triple combination study in heavily pretreated refractory patients. The majority of our patients were either truly cisplatin refractory or had progressed within 12 weeks after cisplatinbased therapy (73%) or even HDCT (78%), indicating a high prevalence of chemotherapy resistance and particularly poor prognosis of these patients. Despite these unfavorable criteria, an encouraging response rate of 51% was observed including 39% complete or marker-negative partial responses. These results compare favorably to the response rates observed in the trials utilizing two drug regimens, in particular, if complete and marker-negative remission are considered (Table 4) . Six of our patients (15%) remain in prolonged CR including two patients who achieved a CR without subsequent resection and one patient who relapsed 4 months after chemotherapy plus resection and was again rendered tumor free by a second salvage surgery (Table 2) . Of note, five of these six patients had previously failed salvage HDCT with autologous stem-cell transplantation. One of the two patients who achieved a complete response without subsequent resection was deemed absolutely cisplatin refractory due to progression during cisplatin-based secondline salvage chemotherapy. Promising activity was also observed with the combination of gemcitabine and oxaliplatin in two phase II trials with response rates of 32% and 46% and complete responses resulting in long-term survival in 10%-12% of patients [14, 21] . Pectasides reported a high response rate with the combination of oxaliplatin and irinotecan; however, these patients had not been pretreated with HDCT and a different definition of resistant disease was used. Einhorn et al. [25] recently described 13% prolonged CRs after gemcitabine and paclitaxel in patients who had failed HDCT in a retrospective analysis. It remains currently unclear whether the addition of a third drug confers a benefit compared with two drug regimens. This question Table 2 . could only be answered within a randomized trial. Unfortunately, given the rare patient population, randomized trials will almost be impossible to conduct. Achieving response rates as high as possible in refractory patients, however, is clinically also important since the induction of a remission may subsequently allow for the complete resection of residual masses and thus offer the potential for long-term survival. The complete resection of residual masses after a chemotherapy-induced remission seems to be an important part in the treatment of these patients, as demonstrated by a retrospective analysis from Indiana University [18] . In this specific analysis of 101 patients with relapsed and/or cisplatin-refractory disease, only 5% of patients achieved long-term survival. All these had surgery of metastatic disease as a vital part of their salvage treatment. A high response rate as achieved with the GOP regimen may allow for a higher number of patients to be resected after chemotherapy. This triple regimen with its high response rate can therefore serve as a therapeutic option for patients with refractory germ-cell cancer and in particular for patients with a high need for a tumor response or patients who may be amenable to surgery after tumor shrinkage.
The GOP regimen was feasible with acceptable toxicity, although a number of patients underwent dose reductions and to a lesser extent dose delays. The relatively high number of dose reductions and delays can be explained by the cautious dose reduction/delay schedule which mandated changes already for grade 2 toxic effects. In particular, no excess neurotoxicity in these heavily cisplatin-pretreated patients was observed despite the combination of two potentially neurotoxic drugs. As expected in such an intensively pretreated patient population, thrombocytopenia was the most frequent grade 3/4 toxicity and occurred in 49% of patients. No hemorrhagic complications, however, occurred. In contrast, a small study of nine patients from Italy utilizing GOP given weekly in germ-cell tumor patients found this combination not to be feasible due to extensive All patients 'resistant' defined as failure to achieve a durable complete remission to a cisplatin-based regimen and one or more of the following unfavorable prognostic features: relapse after CR or progression within 4 weeks after first-line therapy; poor or no response to prior conventional dose cisplatin/ifosfamide therapy; and extragonadal primary site.
b
Refractory being defined as a disease progression during or within 2 months after cisplatin-based chemotherapy.
CI, confidence interval; CR, complete remission; PR, partial remission; NS, not significant; HD-CT, high-dose chemotherapy.
original article Annals of Oncology hematotoxicity, in particular severe thrombocytopenia [26] . Since these patients were comparably heavily pretreated to our patients, the differences in schedule, with gemcitabine given at a dose of 800 mg/m 2 , paclitaxel at 70 mg/m 2 , and oxaliplatin at 50 mg/m 2 once weekly for three consecutive weeks followed by 1 week rest, may have been responsible for the differences in hematotoxicity.
In summary, the triple combination consisting of GOP given as described in this report demonstrates a high activity in platinum-refractory germ-cell tumor patients and may offer a chance for prolonged or even long-term survival in selected patients even after failure of multiple lines of treatment including HDCT. Further development of this regimen in earlier lines of therapy may, however, be challenging. Paclitaxel is already widely used in the second-line setting and is currently being explored as an addition to the BEP regimen in intermediate prognosis patients [27] . All investigations of novel regimens will face the challenge of defining the appropriate clinical setting for second-or even first-line therapy in germcell cancer patients. Clinical situation and inclusion criteria will have to be very carefully chosen. New combinations, however, hold the promise to take us another step forward in treating germ-cell cancer. 
